Evvy sells at-home vaginal-health testing and connected care to people who want a detailed readout of the bacteria and fungi in their vaginal microbiome. A customer collects a vaginal swab, metagenomic sequencing analyzes more than 700 organisms, and a clinician reviews the results before Evvy delivers personalized insights and an action plan that can include prescription-treatment advice for eligible users. The company has closed a $40 million Series B led by Catalio Capital Management.
The commercial loop extends beyond one test. Evvy charges $159 for a one-time Vaginal Health Test or $129 per test through a membership that provides four tests a year, shipped every three months so customers can track how their microbiome evolves. The company also offers health-coaching calls, at-home urinary-tract-infection testing, probiotics, suppositories and symptom-relief products, giving it a mix of individual purchases, subscriptions and related care offerings.
Evvy says it has served more than 100,000 patients and partnered with 3,000 healthcare practitioners; it describes those practitioners as partners rather than people buying the consumer tests. The company also says 96% of patients opt to contribute their data anonymously to clinical research. EvvyAI is the data and analysis platform underlying that research effort, which remains distinct from the clinician-reviewed report and care options delivered to an individual customer.
Beauty Independent described the Series B as oversubscribed and said it brings Evvy’s total capital raised to nearly $60 million. Catalio led the financing, with participation from the U.S. Fertility Innovation Fund, Rethink Impact, Labcorp Venture Fund and existing investors including General Catalyst and Left Lane Capital. Evvy plans to scale EvvyAI, validate studies already underway and expand the consumer service into more doctors’ offices.
Fertility is the first focus for the expanded research operation. Fortune reported that Evvy is collecting samples through prospective studies at IVF clinics and investigating whether novel markers of infection and inflammation are associated with implantation success or failure. That is an effort to discover and validate possible predictive signals, not an established diagnostic for IVF outcomes.
The financing puts Evvy’s two-part strategy under a practical test. Its consumer service must sustain repeat testing and move into clinicians’ offices, while the research program must show that microbiome patterns hold up in prospective fertility studies. Whether those signals become useful inside IVF care will determine if Evvy’s research capability can develop into a second business alongside its tests and care products.